167 related articles for article (PubMed ID: 8026158)
1. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
Houston AK; Jones RN
Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
[TBL] [Abstract][Full Text] [Related]
2. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
[TBL] [Abstract][Full Text] [Related]
4. Bactericidal activity of the new 4-quinolones DU-6859a and DV-7751a.
Morrissey I; Smith JT
J Med Microbiol; 1995 Jul; 43(1):4-8. PubMed ID: 7608954
[TBL] [Abstract][Full Text] [Related]
5. Postantibiotic, postantibiotic sub-MIC, and subinhibitory effects of PGE-9509924, ciprofloxacin, and levofloxacin.
Odenholt I; Löwdin E; Cars O
Antimicrob Agents Chemother; 2003 Oct; 47(10):3352-6. PubMed ID: 14506057
[TBL] [Abstract][Full Text] [Related]
6. Minimum inhibitory concentration quality-control guidelines for biapenem, DU-6859a, FK-037, levofloxacin, grepafloxacin, and ceftizoxime when using various National Committee for Clinical Laboratory Standards susceptibility test methods. Quality Control Study Group.
Bale MJ; Jones RN; Erwin ME
Diagn Microbiol Infect Dis; 1994 May; 19(1):65-8. PubMed ID: 7956017
[TBL] [Abstract][Full Text] [Related]
7. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
Cormican MG; Marshall SA; Jones RN
Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
[TBL] [Abstract][Full Text] [Related]
8. Postantibiotic effects of E-4868 and OPC-17116.
Sanford MD; Jones RN
J Antimicrob Chemother; 1993 Dec; 32(6):916-7. PubMed ID: 8144440
[No Abstract] [Full Text] [Related]
9. [In vitro short-term bactericidal activity and accumulation of NM394, the active metabolite of prulifloxacin, for Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa: comparison with ciprofloxacin, levofloxacin, and gatifloxacin].
Shimizu M; Tabata M; Hara T; Araake M; Watabe H; Nishino T
Jpn J Antibiot; 2002 Dec; 55(6):791-9. PubMed ID: 12621733
[TBL] [Abstract][Full Text] [Related]
10. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
Jones RN; Johnson DM; Biedenbach DJ; Marshall SA
Diagn Microbiol Infect Dis; 1995 Nov; 23(3):123-7. PubMed ID: 8849658
[TBL] [Abstract][Full Text] [Related]
11. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
Nakane T; Iyobe S; Sato K; Mitsuhashi S
Antimicrob Agents Chemother; 1995 Dec; 39(12):2822-6. PubMed ID: 8593031
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the postantibiotic and postantibiotic sub-MIC effects of levofloxacin and ciprofloxacin on Staphylococcus aureus and Streptococcus pneumoniae.
Licata L; Smith CE; Goldschmidt RM; Barrett JF; Frosco M
Antimicrob Agents Chemother; 1997 May; 41(5):950-5. PubMed ID: 9145850
[TBL] [Abstract][Full Text] [Related]
13. Postantibiotic effect and postantibiotic sub-MIC effect of levofloxacin compared to those of ofloxacin, ciprofloxacin, erythromycin, azithromycin, and clarithromycin against 20 pneumococci.
Spangler SK; Lin G; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1998 May; 42(5):1253-5. PubMed ID: 9593160
[TBL] [Abstract][Full Text] [Related]
14. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
Thomson KS; Sanders CC
J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
[TBL] [Abstract][Full Text] [Related]
15. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
[TBL] [Abstract][Full Text] [Related]
16. In vitro activity of gemifloxacin against a broad range of recent clinical isolates from the USA.
McCloskey L; Moore T; Niconovich N; Donald B; Broskey J; Jakielaszek C; Rittenhouse S; Coleman K
J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():13-21. PubMed ID: 10824027
[TBL] [Abstract][Full Text] [Related]
17. Postantibiotic effect of ciprofloxacin compared with that of five other quinolones.
Minguez F; Ramos C; Barrientos S; Loscos A; Prieto J
Chemotherapy; 1991; 37(6):420-5. PubMed ID: 1760941
[TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro antimicrobial activities of the newly synthesized quinolone HSR-903, sitafloxacin (DU-6859a), gatifloxacin (AM-1155), and levofloxacin against Mycobacterium tuberculosis and Mycobacterium avium complex.
Tomioka H; Sato K; Akaki T; Kajitani H; Kawahara S; Sakatani M
Antimicrob Agents Chemother; 1999 Dec; 43(12):3001-4. PubMed ID: 10582897
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin.
Bauernfeind A
J Antimicrob Chemother; 1997 Nov; 40(5):639-51. PubMed ID: 9421311
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic effects of a new quinolone, DU-6859a, on polymicrobial infections in a newly designed model of rat uterine endometritis.
Mikamo H; Kawazoe K; Sato Y; Izumi K; Tamaya T
J Antimicrob Chemother; 1998 Jan; 41(1):131-3. PubMed ID: 9511050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
